Daiwa Securities Group Inc. Allakos Inc. Transaction History

Daiwa Securities Group Inc.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 06, 2023	BUY	$5.66 - $8.42 $1,047 - $1,557	185 Added 117.09%	343 $3,000
Q4 2021 Feb 03, 2022	SELL	$8.55 - $111.89 $230 - $3,021	-27 Reduced 14.59%	158 $2,000
Q3 2021 Nov 05, 2021	BUY	$76.53 - $110.43 $6,198 - $8,944	81 Added 77.88%	185 $20,000
Q1 2021 May 03, 2021	BUY	$109.73 - $153.66 $548 - $768	5 Added 5.05%	104 $12,000
Q4 2020 Feb 04, 2021	SELL	$79.58 - $152.45 $14,006 - $26,831	-176 Reduced 64.0%	99 $14,000
Q4 2019 Jan 31, 2020	SELL	$66.49 - $137.73 $2,194 - $4,545	-33 Reduced 10.71%	275 $26,000
Q3 2019 Nov 04, 2019	BUY	$31.0 - $89.73 $1,240 - $3,589	40 Added 14.93%	308 $24,000
Q1 2019 Apr 26, 2019	SELL	$33.79 - $51.99 $1,081 - $1,663	-32 Reduced 10.67%	268 $11,000
Q4 2018 Feb 05, 2019	BUY	$31.59 - $62.65 $9,477 - $18,795	300 New	300 $16,000

68.8M

20.9K

Ticker ALLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,726,096
Market Cap $22M
Description
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...

Get notified when there are updates to the investment portfolio of Daiwa Securities Group Inc., based on Form 13F filings with the SEC.

Stay updated on Daiwa Securities Group Inc. with notifications on news.